이중 특이성 항체 시장 : 분자 형태별, 기술 플랫폼별, 작용기전별, 약제별, 적응증별, 투여 경로별, 유통 채널별 - 시장 규모, 업계 역학, 기회 분석 및 예측(2026-2035년)

The global bispecific antibodies market is undergoing strong and sustained expansion, reflecting its growing importance within the broader biopharmaceutical and oncology landscapes. In 2025, the market is estimated to be valued at approximately USD 14.4 billion, highlighting the increasing commercial adoption of bispecific antibody therapies across major healthcare systems. This growth is being fueled by continuous innovation in antibody engineering, expanding clinical applications, and rising demand for more targeted and effective treatment options, particularly in areas of high unmet medical need.

Over the forecast period from 2026 to 2035, the market is projected to experience significant upward momentum, reaching an estimated value of around USD 55.9 billion by 2035. This expansion corresponds to a compound annual growth rate (CAGR) of approximately 14.7%, indicating steady and robust long-term growth rather than short-term volatility. The trajectory reflects the transition of bispecific antibodies from a niche therapeutic class into a mainstream component of modern immunotherapy and precision medicine approaches.

Noteworthy Market Developments

The global bispecific antibodies market is currently concentrated among a small group of dominant biopharmaceutical companies that collectively shape innovation, clinical adoption, and commercial growth. These leading players have established strong competitive positions through early investment in bispecific platforms.

Roche stands as the most dominant force in the bispecific antibodies market, commanding approximately 45% market share. The company's leadership is anchored by blockbuster products such as Hemlibra, which generated around USD 6 billion in sales in 2025, and Vabysmo, which contributed approximately USD 5 billion during the same period. AbbVie has also emerged as a key competitor in the bispecific landscape, largely through its oncology-focused portfolio and strategic partnerships. Its therapy EPKINLY (epcoritamab) generated approximately USD 333 million in revenue during the first three quarters of 2025.

Amgen continues to be a foundational player in the bispecific antibody space, having pioneered the first FDA-approved bispecific therapy with blinatumomab in 2014. The company further strengthened its position with the approval of Imdelltra (tarlatamab) in 2024 for small cell lung cancer, developed using its proprietary BiTE platform. Johnson & Johnson plays a significant role in the market through its growing hematology franchise, which includes therapies such as Tecvayli (teclistamab) and Blincyto.

Genmab remains a critical innovation engine in the bispecific antibodies ecosystem, primarily through its proprietary DuoBody platform, which enables the development of highly flexible and effective antibody constructs, including those suitable for subcutaneous administration.

Core Growth Drivers

The global bispecific antibody landscape is undergoing rapid and sustained evolution, supported by a growing wave of regulatory approvals that signal strong and rising market demand. This expanding approval base reflects increasing confidence among global health authorities in the safety, efficacy, and therapeutic value of bispecific antibody platforms. As clinical evidence continues to accumulate across multiple disease areas, regulatory agencies are progressively accelerating their evaluation and authorization processes, contributing to broader global adoption of these advanced biologic therapies.

Emerging Opportunity Trends

The clinical pipeline dynamics in the bispecific antibodies market provide important insight into evolving therapeutic priorities and highlight significant opportunities for continued market growth. The distribution of clinical development programs reflects where innovation is most concentrated and which disease areas are receiving the greatest strategic focus from biopharmaceutical developers. As the field matures, the pipeline increasingly demonstrates a structured progression from early-stage experimentation to late-stage validation, signaling a transition toward more commercially viable and clinically established therapies.

Barriers to Optimization

Leukemia and lymphoma continue to pose significant clinical challenges within the bispecific antibodies market due to their complex disease biology and persistent limitations in long-term treatment outcomes. These hematologic malignancies are often characterized by high relapse rates, particularly after initial lines of therapy, which complicates disease management and reduces overall patient survival prospects. Even when patients respond well to first-line treatments, disease recurrence remains common, creating an ongoing need for more durable and effective therapeutic options.

Detailed Market Segmentation

By mechanism of action, immune cell engagers continue to define the primary growth trajectory of the bispecific antibodies market, accounting for approximately 68% of the total share in 2026. This dominance reflects their strong clinical validation and widespread adoption across oncology indications, where harnessing the patient's own immune system has proven to be one of the most effective therapeutic strategies. Within this category, bispecific antibodies are designed to simultaneously bind to immune effector cells and cancer cells, thereby bridging the two and enabling targeted immune-mediated tumor destruction.

By drug, Blinatumomab continues to stand as the commercial cornerstone of the bispecific antibodies sector, accounting for approximately 42% of total market revenue in 2026. Its sustained leadership reflects both its pioneering status as one of the earliest successfully commercialized bispecific T-cell engager therapies and its continued clinical relevance across multiple treatment settings. Over time, it has established a strong competitive position that remains difficult for newer entrants to displace, largely due to its entrenched clinical adoption and extensive real-world usage data.

By indication, hematologic malignancies remain the dominant therapeutic application area for bispecific antibody interventions, accounting for approximately 72% of global market utilization in 2026. This overwhelming share reflects the strong clinical validation and established success of bispecific platforms in targeting blood-based cancers, where disease biology and treatment accessibility are more conducive to precision immunotherapy approaches. Over time, this segment has evolved into the primary clinical stronghold for bispecific development, supported by extensive trial activity and regulatory approvals across multiple regions.

By route of administration, intravenous delivery continues to serve as the primary foundation for bispecific therapy administration, accounting for approximately 58% of the market share in 2025. This sustained dominance reflects the clinical complexity and stringent delivery requirements associated with bispecific antibody treatments, particularly during the early phases of therapy initiation. Despite ongoing advancements in alternative delivery methods, intravenous infusion remains the most widely adopted and trusted approach in both hospital and specialized clinical settings.

Segment Breakdown

By Molecule Format

• IgG-Like
• Full-Length IgG
• Appended-IgG
• Fragment-Based
• scFv
• Fab
• Fusion / Multispecific

By Technology Platform

• BiTE
• CrossMAb
• DART
• Knob-into-Hole
• Other Proprietary

By Mechanism of Action

• Immune Cell Engagers
• Payload Delivery
• Dual Signaling Blockade

By Drug

• Blinatumomab
• Tarlatamab
• Catumaxomab
• Others

By Indication

• Hematologic Cancers
• Solid Tumors
• Autoimmune & Inflammatory
• Ophthalmology
• Others

By Route of Administration

• Intravenous
• Subcutaneous

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By End User

• Hospitals
• Specialty & Cancer Centers
• Others

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

Geography Breakdown

• North America continues to dominate the global bispecific antibodies sector, holding an estimated 52% market share as of 2026. This leadership position is largely driven by the strong concentration of advanced biotechnology infrastructure and innovation capacity within the region, particularly in research-intensive economies with well-established pharmaceutical pipelines. The dominance reflects not only commercial scale but also deep scientific capability, regulatory maturity, and sustained investment in next-generation biologics development.
• At the center of this regional strength is the United States, which anchors the broader North American biopharmaceutical ecosystem. The country hosts a highly developed network of biopharma companies, academic research institutions, and clinical development organizations that collectively accelerate innovation in antibody engineering. Recent industry data indicate that U.S.-based biopharmaceutical firms have invested more than USD 12 billion in antibody engineering and cell-line optimization programs, underscoring the scale of capital allocation toward improving therapeutic precision, manufacturability, and scalability of bispecific antibody platforms.

Leading Market Participants

• Akeso, Inc
• Amgen
• Roche
• Genentech
• Janssen
• Taisho Pharmaceutical
• Immunocore
• Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Bispecific Antibodies Market

Chapter 2. Research Methodology & Research Framework

• 2.1. Research Objective
• 2.2. Product Overview
• 2.3. Market Segmentation
• 2.4. Qualitative Research
  • 2.4.1. Primary & Secondary Sources
• 2.5. Quantitative Research
  • 2.5.1. Primary & Secondary Sources
• 2.6. Breakdown of Primary Research Respondents, By Region
• 2.7. Assumption for Study
• 2.8. Market Size Estimation
• 2.9. Data Triangulation

Chapter 3. Global Bispecific Antibodies Market Overview

• 3.1. Industry Value Chain Analysis
  • 3.1.1. Research & Antibody Engineering / Discovery Platforms
  • 3.1.2. Cell-Line Development & Biologics CDMOs
  • 3.1.3. Bispecific Antibody Developers & Biopharma Manufacturers
  • 3.1.4. Regulatory, Distribution & Specialty Pharmacy Channels
  • 3.1.5. Hospitals, Cancer Centers & Patients
• 3.2. Industry Outlook
  • 3.2.1. Overview of the Global Bispecific Antibody & Immuno-Oncology Therapeutics Industry
  • 3.2.2. Expanding Approvals and Pipeline Across Hematologic and Solid Tumors
  • 3.2.3. Manufacturing Complexity, CDMO Reliance & Access / Reimbursement Dynamics
• 3.3. PESTLE Analysis
• 3.4. Porter's Five Forces Analysis
  • 3.4.1. Bargaining Power of Suppliers
  • 3.4.2. Bargaining Power of Buyers
  • 3.4.3. Threat of Substitutes
  • 3.4.4. Threat of New Entrants
  • 3.4.5. Degree of Competition
• 3.5. Market Growth and Outlook
  • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.5.2. Price Trend Analysis, By Molecule Format

Chapter 4. Global Bispecific Antibodies Market Analysis

• 4.1. Competition Dashboard
  • 4.1.1. Market Concentration Rate
  • 4.1.2. Company Market Share Analysis (Value %), 2025
  • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Bispecific Antibodies Market Analysis

• 5.1. Market Dynamics and Trends
  • 5.1.1. Growth Drivers
  • 5.1.2. Restraints
  • 5.1.3. Opportunity
  • 5.1.4. Key Trends
• 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 5.2.1. By Molecule Format
    • 5.2.1.1. Key Insights
      • 5.2.1.1.1. IgG-Like
        • 5.2.1.1.1.1. Full-Length IgG
        • 5.2.1.1.1.2. Appended-IgG
      • 5.2.1.1.2. Fragment-Based
        • 5.2.1.1.2.1. scFv
        • 5.2.1.1.2.2. Fab
      • 5.2.1.1.3. Fusion / Multispecific
  • 5.2.2. By Technology Platform
    • 5.2.2.1. Key Insights
      • 5.2.2.1.1. BiTE
      • 5.2.2.1.2. CrossMAb
      • 5.2.2.1.3. DART
      • 5.2.2.1.4. Knob-into-Hole
      • 5.2.2.1.5. Other Proprietary
  • 5.2.3. By Mechanism of Action
    • 5.2.3.1. Key Insights
      • 5.2.3.1.1. Immune Cell Engagers
      • 5.2.3.1.2. Payload Delivery
      • 5.2.3.1.3. Dual Signaling Blockade
  • 5.2.4. By Drug
    • 5.2.4.1. Key Insights
      • 5.2.4.1.1. Blinatumomab
      • 5.2.4.1.2. Tarlatamab
      • 5.2.4.1.3. Catumaxomab
      • 5.2.4.1.4. Others
  • 5.2.5. By Indication
    • 5.2.5.1. Key Insights
      • 5.2.5.1.1. Hematologic Cancers
      • 5.2.5.1.2. Solid Tumors
      • 5.2.5.1.3. Autoimmune & Inflammatory
      • 5.2.5.1.4. Ophthalmology
      • 5.2.5.1.5. Others
  • 5.2.6. By Route of Administration
    • 5.2.6.1. Key Insights
      • 5.2.6.1.1. Intravenous
      • 5.2.6.1.2. Subcutaneous
  • 5.2.7. By Distribution Channel
    • 5.2.7.1. Key Insights
      • 5.2.7.1.1. Hospital Pharmacy
      • 5.2.7.1.2. Retail Pharmacy
      • 5.2.7.1.3. Online Pharmacy
  • 5.2.8. By End User
    • 5.2.8.1. Key Insights
      • 5.2.8.1.1. Hospitals
      • 5.2.8.1.2. Specialty & Cancer Centers
      • 5.2.8.1.3. Others
  • 5.2.9. By Region
    • 5.2.9.1. Key Insights
      • 5.2.9.1.1. North America
        • 5.2.9.1.1.1. The U.S.
        • 5.2.9.1.1.2. Canada
        • 5.2.9.1.1.3. Mexico
      • 5.2.9.1.2. Europe
        • 5.2.9.1.2.1. Western Europe
          • 5.2.9.1.2.1.1. The UK
          • 5.2.9.1.2.1.2. Germany
          • 5.2.9.1.2.1.3. France
          • 5.2.9.1.2.1.4. Italy
          • 5.2.9.1.2.1.5. Spain
          • 5.2.9.1.2.1.6. Rest of Western Europe
        • 5.2.9.1.2.2. Eastern Europe
          • 5.2.9.1.2.2.1. Poland
          • 5.2.9.1.2.2.2. Russia
          • 5.2.9.1.2.2.3. Rest of Eastern Europe
      • 5.2.9.1.3. Asia Pacific
        • 5.2.9.1.3.1. China
        • 5.2.9.1.3.2. India
        • 5.2.9.1.3.3. Japan
        • 5.2.9.1.3.4. Australia & New Zealand
        • 5.2.9.1.3.5. South Korea
        • 5.2.9.1.3.6. ASEAN
        • 5.2.9.1.3.7. Rest of Asia Pacific
      • 5.2.9.1.4. Middle East & Africa (MEA)
        • 5.2.9.1.4.1. Saudi Arabia
        • 5.2.9.1.4.2. South Africa
        • 5.2.9.1.4.3. UAE
        • 5.2.9.1.4.4. Rest of MEA
      • 5.2.9.1.5. South America
        • 5.2.9.1.5.1. Argentina
        • 5.2.9.1.5.2. Brazil
        • 5.2.9.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

• 6.1. Market Dynamics and Trends
  • 6.1.1. Growth Drivers
  • 6.1.2. Restraints
  • 6.1.3. Opportunity
  • 6.1.4. Key Trends
• 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 6.2.1. Key Insights
    • 6.2.1.1. By Molecule Format
    • 6.2.1.2. By Technology Platform
    • 6.2.1.3. By Mechanism of Action
    • 6.2.1.4. By Drug
    • 6.2.1.5. By Indication
    • 6.2.1.6. By Route of Administration
    • 6.2.1.7. By Distribution Channel
    • 6.2.1.8. By End User
    • 6.2.1.9. By Country

Chapter 7. Europe Market Analysis

• 7.1. Market Dynamics and Trends
  • 7.1.1. Growth Drivers
  • 7.1.2. Restraints
  • 7.1.3. Opportunity
  • 7.1.4. Key Trends
• 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 7.2.1. Key Insights
    • 7.2.1.1. By Molecule Format
    • 7.2.1.2. By Technology Platform
    • 7.2.1.3. By Mechanism of Action
    • 7.2.1.4. By Drug
    • 7.2.1.5. By Indication
    • 7.2.1.6. By Route of Administration
    • 7.2.1.7. By Distribution Channel
    • 7.2.1.8. By End User
    • 7.2.1.9. By Country

Chapter 8. Asia Pacific Market Analysis

• 8.1. Market Dynamics and Trends
  • 8.1.1. Growth Drivers
  • 8.1.2. Restraints
  • 8.1.3. Opportunity
  • 8.1.4. Key Trends
• 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 8.2.1. Key Insights
    • 8.2.1.1. By Molecule Format
    • 8.2.1.2. By Technology Platform
    • 8.2.1.3. By Mechanism of Action
    • 8.2.1.4. By Drug
    • 8.2.1.5. By Indication
    • 8.2.1.6. By Route of Administration
    • 8.2.1.7. By Distribution Channel
    • 8.2.1.8. By End User
    • 8.2.1.9. By Country

Chapter 9. Middle East & Africa Market Analysis

• 9.1. Market Dynamics and Trends
  • 9.1.1. Growth Drivers
  • 9.1.2. Restraints
  • 9.1.3. Opportunity
  • 9.1.4. Key Trends
• 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 9.2.1. Key Insights
    • 9.2.1.1. By Molecule Format
    • 9.2.1.2. By Technology Platform
    • 9.2.1.3. By Mechanism of Action
    • 9.2.1.4. By Drug
    • 9.2.1.5. By Indication
    • 9.2.1.6. By Route of Administration
    • 9.2.1.7. By Distribution Channel
    • 9.2.1.8. By End User
    • 9.2.1.9. By Country

Chapter 10. South America Market Analysis

• 10.1. Market Dynamics and Trends
  • 10.1.1. Growth Drivers
  • 10.1.2. Restraints
  • 10.1.3. Opportunity
  • 10.1.4. Key Trends
• 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 10.2.1. Key Insights
    • 10.2.1.1. By Molecule Format
    • 10.2.1.2. By Technology Platform
    • 10.2.1.3. By Mechanism of Action
    • 10.2.1.4. By Drug
    • 10.2.1.5. By Indication
    • 10.2.1.6. By Route of Administration
    • 10.2.1.7. By Distribution Channel
    • 10.2.1.8. By End User
    • 10.2.1.9. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 11.1. Akeso, Inc
• 11.2. Amgen
• 11.3. Roche
• 11.4. Genentech
• 11.5. Janssen
• 11.6. Taisho Pharmaceutical
• 11.7. Immunocore
• 11.8. Other Prominent Players

Chapter 12. Annexure

• 12.1. List of Secondary Sources
• 12.2. Key Country Markets- Macro Economic Outlook/Indicators